Merck KGaA

Guardant is providing its Guardant 360 CDx test for a clinical trial of Merck's small molecule, c-Met kinase inhibitor called tepotinib.

The agreement now includes distribution of Roche's Kapa Biosystems portfolio in all geographies except the US, Brazil, and Japan.

The companies will initially focus on developing a companion diagnostic for Merck's investigational B cell lymphoma drug M7583.